Based on a meta-analysis, NSCLC patients treated with PD-1 inhibitor plus chemotherapy had a lower death risk compared to those treated with PD-L1 inhibitor plus chemotherapy (RR=0.66, 95% CI 0.48-0.90) (18). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.